• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

12.57 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Amneal Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 Next >
News headline image
Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader
April 22, 2026
From Kashiv BioSciences, LLC
Via Business Wire
News headline image
Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance
April 22, 2026
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®
April 20, 2026
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.
April 14, 2026
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Launches Bimatoprost Ophthalmic Solution, 0.01%
April 09, 2026
Important ophthalmic treatment expected to be an important growth driver for Amneal’s Affordable Medicines segment 
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal to Report First Quarter 2026 Results on May 1, 2026
April 07, 2026
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson’s Awareness Month
April 07, 2026
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal to Participate in Upcoming Investor Conference
March 05, 2026
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Reports Fourth Quarter and Full Year 2025 Financial Results
February 27, 2026
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Pharmaceuticals Added to S&P SmallCap 600® Index
January 28, 2026
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026
January 27, 2026
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®
December 22, 2025
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals
December 09, 2025
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease
December 05, 2025
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol
December 02, 2025
Represents second complex respiratory therapeutic product approval in Q4 2025 
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal to Participate in Upcoming Investor Conferences
December 02, 2025
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%
December 01, 2025
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Receives U.S. FDA Approval for Iohexol Injection
November 13, 2025
First-to-market complex injectable with expected launch in Q1 2026 
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Reports Third Quarter 2025 Financial Results
October 30, 2025
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol
October 29, 2025
Company’s first metered-dose inhalation (MDI) product and establishes a new growth vector for the Affordable Medicines segment 
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches
October 27, 2025
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab)
October 06, 2025
From Kashiv BioSciences, LLC and Amneal Pharmaceuticals, Inc. and Alvotech and Advanz Pharma
Via Business Wire
News headline image
Amneal to Report Third Quarter 2025 Results on October 30, 2025
September 30, 2025
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)
September 26, 2025
Potential first-wave entry into the $4+ billion U.S. market and an important new growth driver for Amneal 
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%
September 23, 2025
Important ophthalmic treatment for patients and expected to be a key growth driver for Amneal’s Affordable Medicines segment 
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution
September 11, 2025
Expands Amneal’s Affordable Medicines portfolio and broadens patient access 
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension
September 04, 2025
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Reports Second Quarter 2025 Financial Results
August 05, 2025
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032
July 21, 2025
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results
July 21, 2025
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap